<DOC>
	<DOCNO>NCT00002760</DOCNO>
	<brief_summary>RATIONALE : Antiandrogen withdrawal may effective treatment prostate cancer . PURPOSE : Randomized phase III trial study effectiveness ketoconazole hydrocortisone antiandrogen withdrawal treat men prostate cancer refractory hormone therapy .</brief_summary>
	<brief_title>Antiandrogen Withdrawal Treating Patients With Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare response rate duration response antiandrogen withdrawal alone vs. antiandrogen withdrawal plus ketoconazole/hydrocortisone patient advance hormone-refractory prostate cancer . II . Compare response rate duration response ketoconazole/hydrocortisone patient treat previous vs. simultaneous antiandrogen withdrawal . III . Evaluate proportion patient circulate prostate cancer cell identify reverse transcriptase-polymerase chain reaction ( rt-PCR ) . IV . Determine whether rt-PCR positively correlate response . V. Compare likelihood response regimens patient whose prior hormonal therapy consist initial combined androgen blockage vs. initial monotherapy follow later antiandrogen . VI . Correlate adrenal androgen synthesis suppression , measure level various adrenal androgen , response . OUTLINE : Randomized study . Patients develop progressive disease Arm I cross Arm II . Arm I : Antiandrogen Withdrawal . Antiandrogen stop . Arm II : Antiandrogen Withdrawal plus Adrenal Androgen Blockade . Antiandrogen stop ; plus Ketoconazole , KCZ ; Hydrocortisone , HC , NSC-10483 . PROJECTED ACCRUAL : Approximately 250 patient enter 3 year attain 238 eligible patient ( include 25-40 minority patient ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose adenocarcinoma prostate Progressive metastatic regional nodal disease least 4 week flutamide , bicalutamide , nilutamide , i.e . : Greater 25 % increase sum product perpendicular diameter measurable lesion previously irradiate OR Prostatespecific antigen ( PSA ) least 5 ng/mL rise baseline least 2 successive occasion least 2 week apart PSA progression require `` bone '' disease disease respond androgen deprivation negative imaging scan entry Primary testicular androgen suppression luteinizing hormonereleasing hormone ( LHRH ) analogue plus antiandrogen orchiectomy require Intermittent LHRH analog/antiandrogen therapy resume least 4 week prior continue time entry LHRH analogue continue throughout study absence orchiectomy PATIENT CHARACTERISTICS : Age : Any age Performance status : 02 Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time normal AST great 3 time normal Renal : Not specify Other : No active , uncontrolled condition include : Bacterial , viral , fungal infection Hyperglycemia Gastric duodenal ulcer No exist medical condition require systemic corticosteroid ( inhaled topical steroid allow ) No concurrent use follow : Terfenadine Astemizole Cisapride PRIOR CONCURRENT THERAPY : No prior therapy experimental agent metastatic disease Biologic therapy : No prior immunotherapy metastatic disease Chemotherapy : No prior estramustine chemotherapy metastatic disease Endocrine therapy : See Disease Characteristics No prior hormonal therapy metastatic disease No prior aminoglutethimide No prior ketoconazole No prior hydrocortisone corticosteroids Prior experimental hormonal therapy require approval study chair Radiotherapy : At least 4 week since radiotherapy ( 8 week since strontium therapy ) Surgery : Orchiectomy allow</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>